Taiwo Oladapo

Array ( [id] => 11054485 [patent_doc_number] => 20160251447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'ANTIBODIES THAT SPECIFICALLY BIND ATAXIA TELANGIECTASIA-MUTATED AND RAD3-RELATED KINASE PHOSPHORYLATED AT POSITION 1989 AND THEIR USE' [patent_app_type] => utility [patent_app_number] => 15/027997 [patent_app_country] => US [patent_app_date] => 2014-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 25614 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15027997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10267511 [patent_doc_number] => 20150152508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'NUCLEIC ACID BIOMARKER AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/502792 [patent_app_country] => US [patent_app_date] => 2014-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 26094 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14502792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10262329 [patent_doc_number] => 20150147326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-28 [patent_title] => 'PROTEIN BIOMARKER AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/502769 [patent_app_country] => US [patent_app_date] => 2014-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 21051 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14502769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9917686 [patent_doc_number] => 20150072891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'METHOD FOR DETECTION OF L523S EXPRESSION IN BIOLOGICAL SAMPLES' [patent_app_type] => utility [patent_app_number] => 14/492171 [patent_app_country] => US [patent_app_date] => 2014-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 9859 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14492171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11094058 [patent_doc_number] => 20160291025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'AUTOANTIBODY BIOMARKERS OF OVARIAN CANCER' [patent_app_type] => utility [patent_app_number] => 15/023155 [patent_app_country] => US [patent_app_date] => 2014-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 21361 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15023155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12171089 [patent_doc_number] => 09889206 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-13 [patent_title] => 'C-Met targeting compound-bioactive material conjugate and use thereof' [patent_app_type] => utility [patent_app_number] => 14/485062 [patent_app_country] => US [patent_app_date] => 2014-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 17108 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14485062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14174173 [patent_doc_number] => 10261091 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome [patent_app_type] => utility [patent_app_number] => 14/479084 [patent_app_country] => US [patent_app_date] => 2014-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 29368 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 185 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14479084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10967008 [patent_doc_number] => 20140370040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-18 [patent_title] => 'METHODS FOR IDENTIFYING TUMOR-SPECIFIC POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/478907 [patent_app_country] => US [patent_app_date] => 2014-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 11906 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14478907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10307586 [patent_doc_number] => 20150192587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'USE OF PROTEIN S100A12 AS A MARKER FOR COLORECTAL CANCER' [patent_app_type] => utility [patent_app_number] => 14/463975 [patent_app_country] => US [patent_app_date] => 2014-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13785 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14463975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10998589 [patent_doc_number] => 20160195536 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-07 [patent_title] => 'Materials and Methods Relating to Pancreatic Cancer' [patent_app_type] => utility [patent_app_number] => 14/912299 [patent_app_country] => US [patent_app_date] => 2014-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 19716 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14912299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12143763 [patent_doc_number] => 09877999 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-30 [patent_title] => 'Methods for treating metastatic stage prostate cancer' [patent_app_type] => utility [patent_app_number] => 14/454825 [patent_app_country] => US [patent_app_date] => 2014-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 13807 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14454825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11844586 [patent_doc_number] => 09732131 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-15 [patent_title] => 'Identification and use of novopeptides for the treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/451374 [patent_app_country] => US [patent_app_date] => 2014-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 21 [patent_no_of_words] => 46667 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14451374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10820503 [patent_doc_number] => 20160166667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'DIVALENT VACCINE COMPOSITIONS AND THE USE THEREOF FOR TREATING TUMORS' [patent_app_type] => utility [patent_app_number] => 14/908635 [patent_app_country] => US [patent_app_date] => 2014-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5599 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14908635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10822072 [patent_doc_number] => 20160168236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'ANTI-GALECTIN-1 MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF' [patent_app_type] => utility [patent_app_number] => 14/907362 [patent_app_country] => US [patent_app_date] => 2014-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 31397 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14907362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11277084 [patent_doc_number] => 09493561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Antibodies to Toso' [patent_app_type] => utility [patent_app_number] => 14/322551 [patent_app_country] => US [patent_app_date] => 2014-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 2 [patent_no_of_words] => 16820 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14322551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10939435 [patent_doc_number] => 20140342456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'RNA-Guided Human Genome Engineering' [patent_app_type] => utility [patent_app_number] => 14/318933 [patent_app_country] => US [patent_app_date] => 2014-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 9854 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14318933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10770318 [patent_doc_number] => 20160116474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-28 [patent_title] => 'COMPOSITIONS AND METHODS FOR DETECTING AND TREATING GLIOBLASTOMA' [patent_app_type] => utility [patent_app_number] => 14/898041 [patent_app_country] => US [patent_app_date] => 2014-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 81 [patent_no_of_words] => 25100 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14898041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10953340 [patent_doc_number] => 20140356361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-04 [patent_title] => 'REPEATED ADMINISTRATION OF NON-IMMUNOSUPPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS' [patent_app_type] => utility [patent_app_number] => 14/296204 [patent_app_country] => US [patent_app_date] => 2014-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 29285 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14296204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10767900 [patent_doc_number] => 20160114057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-28 [patent_title] => 'MODULAR PROTEIN DRUG CONJUGATE THERAPEUTIC' [patent_app_type] => utility [patent_app_number] => 14/893706 [patent_app_country] => US [patent_app_date] => 2014-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 42299 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14893706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11218816 [patent_doc_number] => 09447144 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-20 [patent_title] => 'MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1' [patent_app_type] => utility [patent_app_number] => 14/284971 [patent_app_country] => US [patent_app_date] => 2014-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 29 [patent_no_of_words] => 23777 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14284971 [rel_patent_id] =>[rel_patent_doc_number] =>)